Congenital Nephrotic Syndrome

Disclaimer: This information is intended for healthcare professionals and is based on current medical knowledge and guidelines. It is provided for educational purposes and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare provider, taking into account the individual patient's specific circumstances and clinical judgment.

Overview

• Definition: Congenital nephrotic syndrome (CNS) is a rare, severe form of nephrotic syndrome characterized by massive proteinuria, hypoalbuminemia, edema, and hyperlipidemia, with onset occurring within the first three months of life. It is primarily caused by genetic mutations affecting the glomerular filtration barrier.
• Epidemiology: CNS is rare, with an estimated incidence of 1-3 cases per 100,000 live births globally. The highest incidence is observed in Finland (Finnish-type CNS), where it occurs in approximately 1 in 8,000 live births due to a founder mutation in the NPHS1 gene.
• Classification: CNS is predominantly classified by its genetic etiology, though some cases may be secondary to congenital infections.
  • Primary (Genetic) CNS:
    • Finnish-type CNS (NPHS1-related): Caused by mutations in the NPHS1 gene, encoding nephrin. This is the most common form, particularly in Finland.
    • NPHS2-related CNS: Caused by mutations in the NPHS2 gene, encoding podocin. Can also cause early-onset nephrotic syndrome, but often presents later than Finnish-type.
    • WT1-related disorders: Mutations in the WT1 gene can lead to Denys-Drash syndrome (DDS), characterized by CNS, male pseudohermaphroditism, and Wilms tumor; and Frasier syndrome (FS), characterized by focal segmental glomerulosclerosis, gonadal dysgenesis, and increased risk of gonadoblastoma.
    • LAMB2-related CNS: Mutations in the LAMB2 gene, encoding laminin β2, causing Pierson syndrome, which includes CNS, ocular abnormalities (microcoria), and neurological deficits.
    • Other rare genetic causes: Including mutations in PLCE1 (NPHS3, diffuse mesangial sclerosis), TRPC6, CD2AP, ACTN4, INF2, MYH9, COQ2, LMX1B, and many others increasingly identified with next-generation sequencing.
  • Secondary CNS (Rare): Due to congenital infections such as cytomegalovirus (CMV), syphilis, toxoplasmosis, or rubella. These are much less common as causes of true congenital nephrotic syndrome with massive proteinuria.

Pathophysiology

• Mechanism: The underlying mechanism involves inherited defects in the genes encoding proteins essential for the structural and functional integrity of the glomerular slit diaphragm or basement membrane. These proteins, primarily nephrin and podocin, are crucial components of the podocyte foot processes, which form the highly selective filtration barrier in the glomerulus. Mutations lead to a dysfunctional or absent slit diaphragm, resulting in massive leakage of plasma proteins (especially albumin) into the urine.
• Risk Factors:
  • Genetic predisposition: Positive family history of CNS or early-onset nephrotic syndrome.
  • Parental carrier status for recessive mutations (e.g., NPHS1, NPHS2).
  • Specific ethnic backgrounds (e.g., Finnish population for NPHS1).
• Protective Factors: There are no known protective factors against the genetic predisposition to CNS. However, early diagnosis and aggressive supportive management can mitigate severe complications and improve long-term outcomes, especially regarding growth and survival until kidney transplantation.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Massive edema: Generalized edema (anasarca), often present at birth or developing within the first few weeks of life, affecting the face, eyelids, abdomen (ascites), and extremities.
  • Hypoalbuminemia: Serum albumin levels typically <2.5 g/dL, often much lower (<1.0 g/dL).
  • Proteinuria: Profound proteinuria, typically >40 mg/m²/hour or urine protein-to-creatinine ratio (UPCR) >2-3 g/g, or 24-hour urine protein >1 g/day. Foam or frothy urine may be noted.
  • Hyperlipidemia: Elevated serum cholesterol and triglycerides.
• Early Signs:
  • Large placenta (often >25% of birth weight, especially in Finnish-type CNS).
  • Mild anasarca or facial puffiness noted shortly after birth.
  • Poor feeding, irritability, lethargy.
• Advanced Signs:
  • Failure to thrive and poor growth, despite adequate caloric intake.
  • Recurrent infections (e.g., peritonitis, sepsis, pneumonia) due to loss of immunoglobulins (IgG) and impaired immune function.
  • Thrombotic events (e.g., renal vein thrombosis, deep vein thrombosis, pulmonary embolism, cerebral venous sinus thrombosis) due to loss of anticoagulant proteins (e.g., antithrombin III) and increased procoagulant factors.
  • Respiratory distress due to pleural effusions or severe ascites compressing the diaphragm.
  • Ascites causing abdominal distension and discomfort.
  • Hypovolemic crises.
  • Progressive renal insufficiency.
• Atypical Presentations:
  • Depending on the specific genetic mutation, associated extra-renal features may be present (e.g., ambiguous genitalia, Wilms tumor risk in Denys-Drash syndrome; ocular abnormalities and neurological defects in Pierson syndrome).
  • Some genetic forms (e.g., NPHS2) may present later in infancy or childhood.

Physical Examination

• Inspection:
  • Generalized pitting edema, prominent in the face, eyelids, and dependent areas.
  • Abdominal distension (ascites).
  • Scrotal/labial edema.
  • Respiratory distress (tachypnea, grunting, retractions) if significant pleural effusions or ascites.
  • Pallor (due to chronic anemia, common).
  • Poor growth parameters for age.
• Palpation:
  • Pitting edema.
  • Fluid thrill or shifting dullness on abdominal palpation, indicating ascites.
  • Hepatomegaly due to fluid overload or fatty infiltration.
• Special Tests: No specific tests beyond thorough physical examination; focus on signs of fluid overload, infection, and thrombosis.

Diagnostic Approach

History Taking

• Key Questions:
  • Age of onset and progression of edema.
  • Family history of kidney disease, early childhood deaths, or nephrotic syndrome.
  • Maternal history: Any complications during pregnancy (e.g., pre-eclampsia, though rare for true CNS).
  • Detailed history of growth, feeding, and infections.
  • Presence of any extra-renal symptoms (e.g., ambiguous genitalia, visual problems).
• Red Flags:
  • Onset of anasarca in the first 3 months of life.
  • Rapidly worsening edema.
  • Signs of infection (fever, irritability, poor feeding).
  • Signs of thrombosis (limb swelling, cyanosis, neurological changes).

Laboratory Tests

• First-Line:
  • Urinalysis: Dipstick typically shows 3+ to 4+ protein. Microscopic examination may reveal fatty casts (oval fat bodies).
  • Urine protein-creatinine ratio (UPCR): Elevated, typically >2-3 g/g, confirming massive proteinuria. A 24-hour urine collection (often impractical in infants) would show >1 g/day or >40 mg/m²/hour.
  • Serum albumin: Markedly reduced, usually <2.5 g/dL, often <1.0 g/dL.
  • Serum creatinine and BUN: Initially normal, but may rise with dehydration or progressive renal failure.
  • Electrolytes: May show hyponatremia due to dilutional effect, hyperkalemia if renal failure ensues.
  • Lipid panel: Elevated total cholesterol, LDL, and triglycerides.
  • Complete Blood Count (CBC): May show anemia (due to hemodilution, iron deficiency, or chronic disease), leukocytosis (if infection present).
  • C-reactive protein (CRP) and Procalcitonin: To screen for infection.
  • Coagulation profile: Evaluate for hypercoagulability (e.g., elevated D-dimer, fibrinogen).
• Confirmatory:
  • Genetic Testing: A comprehensive gene panel for nephrotic syndrome (including NPHS1, NPHS2, WT1, LAMB2, PLCE1, etc.) is the definitive diagnostic test. This often negates the need for renal biopsy.
  • Renal Biopsy: May be considered if genetic testing is negative or for atypical presentations, or to assess the extent of glomerular damage (e.g., diffuse mesangial sclerosis). Histology may show variable findings depending on the genetic cause (e.g., sparse foot processes, effacement, microcystic changes, diffuse mesangial sclerosis).
  • Congenital Infection Screen: If genetic testing is negative, evaluate for TORCH infections (Toxoplasmosis, Other [syphilis, parvovirus], Rubella, Cytomegalovirus, Herpes simplex) via serology (IgM/IgG) and/or PCR from urine/blood.
• Monitoring:
  • Daily weights and fluid balance.
  • Serial UPCR, serum albumin, creatinine, electrolytes.
  • Growth parameters (height, weight, head circumference).
  • Infection markers (CRP, procalcitonin) during febrile episodes.
  • Coagulation factors (e.g., antithrombin III, protein C/S) and D-dimer if thrombosis is suspected.
  • Immunoglobulin levels (IgG) to guide replacement therapy.

Imaging

• Recommended:
  • Renal Ultrasound: Usually normal in size and echotexture initially, but may show increased echogenicity or cystic changes later if diffuse mesangial sclerosis is present. Essential to rule out structural anomalies.
  • Abdominal Ultrasound: To assess for ascites, pleural effusions, and to screen for Wilms tumor in WT1-related cases.
  • Chest X-ray: To assess for pleural effusions or pulmonary edema if respiratory distress is present.
• Advanced:
  • CT/MRI of brain: If neurological symptoms suggest thrombosis (e.g., stroke).
  • Doppler ultrasound: For suspected deep vein thrombosis.

Management

Acute Management

• Immediate:
  • Fluid resuscitation: For hypovolemia (often masked by generalized edema), cautious intravenous crystalloids or albumin (e.g., 25% albumin, 0.5-1 g/kg IV over 2-4 hours). Monitor vital signs closely.
  • Diuresis: Follow albumin infusion with loop diuretics (e.g., furosemide 1-2 mg/kg IV or PO) to mobilize edema fluid.
• Stabilization:
  • Fluid and electrolyte management: Strict fluid restriction (often 50-70% of maintenance) tailored to urine output and edema status. Careful monitoring of serum electrolytes for hyponatremia and hyperkalemia.
  • Nutritional support: Aggressive, high-calorie, high-protein diet (up to 150% of recommended daily allowance) to counter protein losses and promote growth. Often requires continuous or bolus nasogastric or gastrostomy tube feeds.
  • Infection prevention: Meticulous hygiene, prophylactic antibiotics (e.g., penicillin or trimethoprim-sulfamethoxazole) in cases of recurrent severe infections, especially peritonitis.
  • Immunoglobulin replacement: Intravenous immunoglobulin (IVIG) may be considered for severe hypogammaglobulinemia (IgG <200-400 mg/dL) or recurrent serious infections.
• Emergency:
  • Respiratory support: Oxygen, positive pressure ventilation for severe pleural effusions or ascites causing respiratory compromise. Thoracentesis or paracentesis may be necessary.
  • Sepsis management: Prompt administration of broad-spectrum antibiotics, fluid resuscitation, and inotropic support as per sepsis protocols.
  • Thrombosis management: Acute thrombosis requires immediate anticoagulation (e.g., unfractionated heparin, then low molecular weight heparin). Consider prophylactic anticoagulation in high-risk patients.

Chronic Management

• Pharmacological:
  • Diuretics: Continue loop diuretics (e.g., furosemide), often combined with thiazide diuretics (e.g., hydrochlorothiazide 1-2 mg/kg/day PO) or potassium-sparing diuretics (e.g., spironolactone 1-3 mg/kg/day PO) for sustained diuresis and electrolyte balance.
  • Albumin infusions: Regular infusions (e.g., 25% albumin, 0.5-1 g/kg IV 1-3 times per week) to maintain oncotic pressure, reduce edema, and provide protein, especially before or during infections, or when severely symptomatic. Always followed by diuretics.
  • ACE inhibitors/ARBs: May be used cautiously to reduce proteinuria in some non-CNS nephrotic syndromes, but their role in CNS is limited and controversial due to risk of hyperkalemia and acute kidney injury, especially with severe disease. Not standard primary treatment.
  • NSAIDs (Indomethacin): Rarely used in CNS due to significant renal and gastrointestinal side effects and limited efficacy in the severe protein loss characteristic of CNS. Generally not recommended.
  • Anticoagulation: Prophylactic low molecular weight heparin (LMWH) may be considered in patients with very low antithrombin III levels (e.g., <50-70%) or a history of thrombosis, given the high risk.
  • Thyroid hormone replacement: For patients with hypothyroidism secondary to thyroid-binding globulin loss.
  • Vitamin D supplementation: For bone health.
• Non-pharmacological:
  • Nutritional management: Continued high-calorie, high-protein intake, often requiring supplemental feeding via nasogastric or gastrostomy tube. Monitor for micronutrient deficiencies (e.g., iron, zinc).
  • Fluid restriction: Tailored to edema status.
  • Infection control: Scrupulous skin care, avoidance of crowded environments, and immunization as per schedule.
  • Psychosocial support: For patients and families dealing with chronic illness.
• Monitoring:
  • Regular assessments of growth and development.
  • Frequent laboratory monitoring (electrolytes, renal function, albumin, protein, lipids, CBC).
  • Infection surveillance and prompt treatment.
  • Screening for thrombotic events.
  • Bone health monitoring.

Treatment Algorithms

• First-Line:
  1. Diagnosis Confirmation: Genetic testing is crucial for specific diagnosis and prognosis.
  2. Supportive Care:
     • Aggressive management of edema (albumin infusions + diuretics).
     • Optimized nutritional support (often via tube feeding).
     • Prevention and prompt treatment of infections (IVIG if severe hypogammaglobulinemia).
     • Prophylaxis/treatment of thrombosis.
  3. Preparation for Kidney Transplantation: CNS inevitably leads to end-stage renal disease (ESRD). Kidney transplantation is the definitive treatment.
• Second-Line:
  • Bilateral Nephrectomy: Often performed electively when patients are stable (typically 6-12 months of age or weight >7-10 kg) to significantly reduce massive protein loss, improve nutritional status, decrease infection risk (especially peritonitis), and better prepare the child for transplantation. This necessitates initiation of dialysis.
• Refractory Cases:
  • For patients with severe, life-threatening complications (e.g., intractable edema, recurrent severe infections, severe growth failure) despite aggressive medical management, earlier bilateral nephrectomy and initiation of dialysis, followed by transplantation, may be indicated.

Complications

• Common:
  • Infections: Most common cause of morbidity and mortality due to hypogammaglobulinemia (loss of IgG) and immune dysfunction. Peritonitis, cellulitis, pneumonia, sepsis.
  • Thrombosis: High risk of arterial and venous thrombosis (renal vein, deep vein, cerebral venous sinus thrombosis) due to loss of anticoagulant proteins (e.g., antithrombin III, protein C/S) and increased levels of procoagulant factors (e.g., fibrinogen).
  • Severe edema: Leading to skin breakdown, respiratory distress, and discomfort.
  • Growth failure: Due to protein losses, chronic illness, and often inadequate nutritional intake.
  • Hypothyroidism: Due to loss of thyroid-binding globulin.
  • Anemia: Due to hemodilution, chronic inflammation, or iron deficiency.
• Serious:
  • Sepsis and septic shock.
  • Acute kidney injury (AKI) from hypovolemia, infection, or medication side effects.
  • Thrombotic stroke or pulmonary embolism.
  • Death (often from infection or thrombosis).
• Long-term:
  • End-stage renal disease (ESRD), requiring dialysis and kidney transplantation.
  • Neurodevelopmental delays due to chronic illness, repeated hospitalizations, and potential complications like stroke.
  • Bone disease (renal osteodystrophy).
  • Psychosocial burden on patient and family.

Prognosis

• Factors:
  • Genetic mutation: Prognosis varies depending on the specific gene mutation. For instance, Finnish-type CNS (NPHS1) often has a slower progression to ESRD and a better prognosis post-transplant compared to diffuse mesangial sclerosis (PLCE1 or WT1), which can progress very rapidly.
  • Aggressiveness of supportive care: Early diagnosis, prompt and aggressive management of edema, nutritional support, and infection/thrombosis prevention significantly improve short-term survival.
  • Access to kidney transplantation: The availability and success of kidney transplantation are the most critical factors for long-term survival.
• Survival: Historically, CNS had a very poor prognosis, with many infants dying within the first year of life. With advances in supportive care, dialysis, and kidney transplantation, survival rates have significantly improved. Most children with CNS will progress to ESRD, typically by 2-8 years of age. Overall 5-year survival rates post-transplant for children with CNS are comparable to other pediatric kidney transplant recipients.
• Quality of Life: Quality of life is significantly impacted by chronic illness, frequent hospitalizations, need for tube feeding, dialysis, and immunosuppression post-transplant. Neurodevelopmental outcomes require close monitoring and support.

Prevention

• Primary:
  • Genetic Counseling: For families with a known history of CNS or identified carrier status for CNS-associated genes, pre-conception or prenatal genetic counseling is crucial.
  • Prenatal Diagnosis: In families with a known genetic mutation, prenatal diagnosis via chorionic villus sampling or amniocentesis can be performed.
• Secondary:
  • Early Detection: Awareness among pediatricians and neonatologists of CNS as a cause of early-onset edema is vital for prompt diagnosis. A large placenta at birth can be an early clue.
  • Early Intervention: Rapid initiation of supportive therapy after diagnosis to mitigate complications.
• Tertiary:
  • Prevention of Complications: Aggressive management of infections, fluid overload, thrombosis, and nutritional deficiencies.
  • Timely Referral: Prompt referral to a pediatric nephrology center for comprehensive care and evaluation for kidney transplantation.

Special Populations

• Pediatric: CNS is inherently a pediatric condition. All management strategies are tailored to the specific physiological needs of infants and young children, considering growth, development, and the unique challenges of chronic illness in this age group.
• Geriatric: Not applicable.
• Pregnancy: This condition primarily affects the infant. For mothers who are carriers of CNS genes, genetic counseling and prenatal diagnosis options are relevant for future pregnancies.
• Comorbidities:
  • Wilms Tumor Risk: Patients with WT1 mutations (Denys-Drash syndrome) require regular renal ultrasound screening for Wilms tumor (e.g., every 3 months until age 7-8 years).
  • Gonadal Dysgenesis: Patients with WT1 mutations may require evaluation for gonadal dysgenesis and, if present, gonadectomy to prevent gonadoblastoma.
  • Ocular and Neurological Deficits: In Pierson syndrome (LAMB2), ophthalmological and neurological evaluations are crucial.

Clinical Pearls

• Diagnostic:
  • Always consider congenital nephrotic syndrome in any infant presenting with generalized edema (anasarca) within the first three months of life, especially if accompanied by massive proteinuria and hypoalbuminemia.
  • A historically large placenta (>25% of birth weight) is a strong clue, particularly for Finnish-type CNS.
  • Genetic testing is the gold standard for definitive diagnosis and often obviates the need for renal biopsy.
• Treatment:
  • Aggressive nutritional support is paramount to counter protein losses and promote growth; tube feeding is often necessary.
  • Bilateral nephrectomy is a bridge to transplant, significantly reducing protein loss and improving patient stability, but it mandates dialysis until transplantation.
  • Strict fluid management combined with albumin infusions and diuretics is crucial for managing severe edema.
  • Maintain a high index of suspicion for infection and thrombosis, as these are the leading causes of morbidity and mortality.
• Pitfalls:
  • Underestimating the severity of protein loss and its impact on nutrition and immune status.
  • Delay in diagnosing or treating infections and thrombotic events.
  • Inadequate fluid management leading to either dehydration (despite edema) or severe fluid overload.
  • Delay in genetic testing, which can inform prognosis and management strategy.

Recent Updates

• Guidelines: Current pediatric nephrology guidelines emphasize early genetic diagnosis and comprehensive supportive care aimed at preparing the child for kidney transplantation. KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for chronic kidney disease and glomerulonephritis provide general principles applicable to CNS.
• Evidence: Ongoing research continues to identify new genetic mutations associated with CNS, expanding the understanding of its pathophysiology. Advances in pediatric critical care, dialysis modalities, and kidney transplantation techniques have significantly improved patient outcomes.
• Controversies:
  • Optimal timing for bilateral nephrectomy: While generally accepted as beneficial, the exact timing and the balance between managing complications vs. maintaining residual renal function until transplant remains a topic of discussion.
  • Role of specific pharmacologic agents (e.g., indomethacin, ACE inhibitors) in protein reduction for CNS: Generally, these are not effective in the severe forms of CNS and carry significant side effect risks.

Key References

• Guidelines:
  • KDIGO Clinical Practice Guideline for Glomerular Diseases (relevant sections on nephrotic syndrome). Available via Kidney International Supplements.
  • ESPN/ERA-EDTA Registry reports on congenital nephrotic syndrome outcomes.
• Studies:
  • Jalanko H. Congenital nephrotic syndrome. Pediatric Nephrology 2009;24(12):2305-12. (Classic review on Finnish-type CNS)
  • Sadowski CE, et al. New Insights into the Genetics of Nephrotic Syndrome. Kidney International 2017;91(6):1314-1327. (Review on genetic causes)
  • Trautmann A, et al. New Treatment Strategies in Primary Nephrotic Syndrome. Journal of the American Society of Nephrology 2021;32(1):15-28. (While not exclusively CNS, discusses principles applicable to severe nephrotic syndrome).
• Reviews:
  • Lombel RM, et al. Congenital nephrotic syndrome: A review of the genetic causes and management. Clinical Nephrology 2021;95(2):67-78.
  • Webb N, et al. Congenital Nephrotic Syndrome: A Modern Management Overview. Pediatric Drugs 2019;21(5):373-381.

---

Medical Disclaimer: This comprehensive clinical reference is provided for informational and educational purposes only for healthcare professionals. It is not intended as medical advice for individual patients and should not be used as a substitute for professional diagnosis or treatment. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to patient care. Clinical practice guidelines and evidence are constantly evolving, and readers are encouraged to consult the most current authoritative sources.